Kolltan Pharmaceuticals
Developing novel biologic drugs targeting receptor tyrosine kinases (RTKs) for oncology and immunology.
Launch date
Employees
Market cap
-
Enterprise valuation
$235m (Public information from Nov 2016)
New Haven Connecticut (HQ)
Authorizing premium user...